Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Aneka, Kalbe Farma, Ramayana Lestari: Indonesia Equity Preview

Shares of the following companies may have unusual moves in Indonesian trading. Stock symbols are in parentheses, and share prices are as of the previous close.

The Jakarta Composite index gained 0.7 percent to 3,537.18.

PT Aneka Tambang (ANTM IJ): The company’s first-half audited net income rose 35 percent from a year earlier to 1.02 trillion rupiah ($116 million), Aneka Tambang, the nation’s second-largest nickel producer, said in a statement published in Investor Daily today. Aneka Tambang fell 0.7 percent to 1,440 rupiah.

PT Clipan Finance Indonesia (CFIN IJ): The leasing and consumer financing company plans to sell as much as 500 billion rupiah of bonds in October to boost working capital, it said in a statement published today in Bisnis Indonesia. Clipan Finance declined 2.3 percent to 435 rupiah.

PT Kalbe Farma (KLBF IJ): Southeast Asia’s largest drugmaker created a three-person team to help it find acquisitions in the region, including producers of consumer health-care products, Chief Financial Officer Vidjongtius said. Kalbe Farma climbed 1.6 percent to 3,275 rupiah.

PT Ramayana Lestari Sentosa (RALS IJ): The retailer expects to increase sales by 20 percent in 2012, Kontan reported, citing Setyadi Surya, a director at the company. Ramayana plans to boost sales by 14 percent this year, the newspaper said. The stock fell 1.4 percent to 680 rupiah.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.